Synthace
Engineering biology for health, food, energy and manufacturing..
- B2B
- manufacturing
- health
- robotics
- biotechnology
- artificial intelligence
- hardware
- deep tech
- machine learning
- nanotech
- biotechnology
- sustainable development goals
- dt and ls
- spinout
- core ai
- ai applications
- drug development
- nif defense security and resilience
- ai drug discovery
- techbio
- tech for biotech and pharma
- synthetic biology
- digital pharma
- techbio drug discovery
- nif health crisis preparedness
- medical robots
- compbio
- nif biotech
- bia techbio uk
- lab automation
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $35.0m | Series C | |
| Total Funding | 000k | ||
| GBP | 2012 | 2013 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 406 % | 25 % | 107 % | 47 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (61518 %) | - | 205 % | (1501 %) | (724 %) | (548 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (62348 %) | - | 118 % | (1465 %) | (660 %) | (480 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Synthace operates in the life sciences sector, providing a cloud-based software platform designed to automate experimentation and facilitate insight sharing. The platform, known as Synthace Life Sciences R&D Cloud, enables scientists to create and share automated workflows without needing programming or automation expertise. This allows researchers to focus on impactful work by reducing the time and effort required for manual processes. The platform supports advanced experimental designs like Design of Experiments (DOE) and Quality by Design (QbD), which help in testing multiple factors and their interactions simultaneously. Synthace serves life science researchers and organizations looking to enhance their R&D capabilities, improve data reproducibility, and maximize the efficiency of their experimental processes. The company generates revenue through subscription fees for its software platform, targeting a market that includes academic institutions, biotech firms, and pharmaceutical companies.
Keywords: life sciences, R&D automation, cloud platform, experimentation, insight sharing, DOE, QbD, data reproducibility, biotech, pharmaceutical.